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ttp://dx.doi.org/10.1016/j.jmoldx.2013.10.006Traditional carrier screening assays are designed to look for only the most common mutations within a
gene owing to cost considerations. Although this can yield high detection rates in speciﬁc populations
for speciﬁc genes (such as cystic ﬁbrosis in Caucasians), they are suboptimal for other ethnicities or
for patients of mixed or unknown ethnic background. Next-generation DNA sequencing provides an
opportunity to provide carrier screening using more comprehensive mutation panels that are limited
primarily by information about the clinical impact of detected sequence changes. We describe a next-
generation DNA sequencing-based assay capable of reliably screening patient samples in a timely and
comprehensive manner. The analytic accuracy in a research setting has been documented. Here, we
describe the additional studies performed to ensure the accuracy (analytic validity) and robustness of
our assay for use in clinical practice and provide data from our experience offering this testing. Our
clinical experience using this approach to screen 11,691 in vitro fertilization patients has identiﬁed
449 mutant alleles: 447 in carriers and 2 in an affected individual. In total, we found 87 distinct
mutations in 14 different genes. Approximately one quarter of the mutations found are not included in
traditional, limited, mutation panels, including 16 known mutations unique to our panel, and novel
truncating mutations in several genes. (J Mol Diagn 2014, 16: 180e189; http://dx.doi.org/10.1016/
j.jmoldx.2013.10.006)Disclosures: All authors are employees of Good Start Genetics, Inc.
(Cambridge, MA). In addition, all full-time employees (S.H., H.N., V.G.,
J.D., N.F., D.N., K.C., M.A.U., N.C., A.C.K., G.J.P., and C.J.K.) have
stock options in the company and hence are potential future shareholders in
Good Start Genetics, Inc. M.A.U., C.J.K., G.J.P., and V.G. are listed as
inventors on patents or patent applications related to this work.Next-generation DNA sequencing (NGS) holds the prom-
ise of providing high-throughput, accurate carrier screen-
ing for multiple genes and multiple mutations in a highly
efﬁcient manner in clinical laboratories.1 To date, NGS
has found application in evaluating affected individuals
for numerous multigene disorders and for elucidating
the correct diagnosis and hence treatment of patients
with various forms of cancer,2 but carrier screening assay
development has been slower because of concerns about
accuracy3,4 and throughput in a clinical setting. Here, we
describe the validation for clinical use of the ﬁrst multi-
gene carrier screening assay using NGS technology to be
offered in the United States and provide information about
our clinical experience thus far.stigative Pathology
.The genes included in our assay have proven clinical val-
idity (the association between mutations in the gene and the
related disorder has been established).5,6 In addition, carrier
testing for these genes is recommended by the American
College of Medical Genetics and Genomics, the American
Congress of Obstetricians and Gynecologists, and/or are
assessed routinely in persons of Ashkenazi Jewish descent
because of the increased carrier frequency in this population
Carrier Screening Using NGSand/or their clinical severity. The NGS panel validated the
following diseases (gene symbols are shown in parentheses):
Canavan disease (ASPA), cystic ﬁbrosis (CFTR), glycogen
storage disorder type 1a (G6PC), Niemann-Pick disease
(SMPD1), Tay-Sachs disease (HEXA), Bloom syndrome
(BLM ), Fanconi anemia C (FANCC ), familial hyperinsulin-
ism (ABCC8), maple syrup urine disease type 1A (BCKDHA)
and type 1B (BCKDHB), Usher syndrome type III (CLRN1),
dihydrolipoamide dehydrogenase deﬁciency (DLD), familial
dysautonomia (IKBKAP), mucolipidosis type IV (MCOLN1),
and Usher syndrome type 1F (PCDH15). Additional genes
and mutations, for which the gene or mutations are not readily
evaluated by NGS, are assessed by alternate methodologies to
ensure detection of clinically important mutations. The vali-
dations for these alternate methodologies followed standard,
clinical laboratory procedures and are not described here.
Clinical carrier screening assays traditionally have
assessed a limited set of mutations, typically those prevalent
in speciﬁc ethnic groups. NGS provides the possibility of
ﬁnding a much larger set of sequence variants across many
ethnic groups. Because NGS is not limited to a small
number of mutations, there is an additional dilemma related
to the interpretation and reporting of the variants detected.
Certainly, this is one of the most challenging areas associ-
ated with the advent of NGS technology in the carrier
screening arena. Extensive discussions and feedback from
our clinical and genetic counselor advisory boards has
indicated that speciﬁcity was an important factor in offering
carrier screening using NGS. In addition, others advocating
a responsible approach to offering full sequencing recom-
mend reporting only those variants that are known to have a
clinical impact7 (ie, no variants of unknown signiﬁcance).
After determination of the panel of genes to be assessed,
it was essential to our clinical approach to rigorously
establish the variants that must be detected for multifold
reasons, including the following: i) to complete a compre-
hensive evaluation of all available information about each
variant for each gene to determine the full list of mutations
that were considered pathogenic; ii) to put this information
into a variant database that could be curated, managed, and
updated periodically to ensure that new information about
variants could be added and that the panel would remain
pertinent (this information then can be used for future
cases); iii) to have a system that would integrate with the
NGS data analysis pipeline to ensure rapid and consistent
calling of clinically relevant mutations; and iv) to ensure
that all variants that passed our ﬁlters for being pathogenic
and clinically important could be either readily detected by
the NGS assay or an alternate methodology to ensure
detection. These alternate methodologies have all been used
in clinical laboratories performing carrier testing for a
number of years and hence are not discussed further (they
were all validated before use in our laboratory).
This latter consideration is important and one that is gaining
awareness among those using or considering using NGS
technology for clinical applications. Some genes, gene regions,The Journal of Molecular Diagnostics - jmd.amjpathol.orgor mutations are particularly problematic for NGS and vary
with the technology and analysismethod(s) used. For example,
pseudogenes,GC-rich regions, homopolymers, largedeletions,
and complex insertions/deletions all can be problematic de-
pending on the speciﬁc sample preparation, sequencing, and
analysis method(s) used.8 Hence, our approach was to maxi-
mize the extent of what is addressable by NGS and to ensure
detection of all clinically important mutations.
Because NGS has the ability to detect additional sequence
variants in genomic regions sequenced at high quality and
depth, we established a pathway for assessment of novel,
reportable variants whereby a patient’s DNA sequence is
scanned for variants that meet one or more of the following
criteria: i) occurs at a conserved donor or acceptor splice site
(2 bases of intron), ii) generates a premature stop codon
(nonsensemutation), or iii) generates a frame-shift in theprotein
sequence.When a stopcodonor frame-shiftmutation is present,
the position of the mutation relative to the 30 most truncating
mutation previously described for the disorder also is taken into
account. These mutations are reported as predicted to be path-
ogenic and further increase the detection rates for each disorder
beyond what has been reported previously as pathogenic.
Before beginning the validation of the clinical NGS
assay, it was necessary to deﬁne acceptable analytic sensi-
tivity and speciﬁcity criteria. To use an NGS assay for
carrier screening, we required a high level of clinical con-
ﬁdence that the assay would not miss carriers. Hence, we
were most concerned about the false-negative rate. All
positive results were conﬁrmed by Sanger sequencing,
thereby eliminating false-positive results before clinical
reporting. Studies detailing assay design and analytic ac-
curacy in a research setting already have been described.1 In
brief, it was shown that NGS could achieve a false-negative
rate of 2.52  104 (95% Wilson binomial conﬁdence in-
terval, 1.29  105 1.42  103) for single-nucleotide
variants; a single false-negative call occurred in a sample
previously characterized as aneuploid.9 For insertions, de-
letions, or the more complex mutations that are indels, three
false-negative results occurred. However, there were no
false-negative results for any position in the sequence where
a pathogenic mutation of interest occurred, as deﬁned in our
variant database, and/or that was not covered by an alternate
methodology. Our goal therefore was to show a false-
negative rate of zero in the validation studies described later.
As mentioned earlier, in this study, Sanger sequencing
was used as the comparator method for the analytic accu-
racy studies, despite the high cost and resource burden of
fully sequencing each sample for each of the genes in the
NGS panel. This can be leveraged for future validations.
For the purpose of clinical testing, it is necessary to be
able to Sanger sequence any amplicon for any gene that is
assessed by NGS to conﬁrm the presence of the mutation,
and therefore we also validated Sanger sequencing for
approximately 250 amplicons.
To offer a clinical-grade carrier screening assay with
high accuracy and precision (reproducibility), robustness,181
Hallam et althroughput, and a rapid turnaround time, it was necessary to
complete a thorough validation. At the time our validation plan
was set, there were no published guidelines on validation of
NGS assays. Instead, we used a blended approach of profes-
sional society recommendations and the experience of the
technical, clinical, and bioinformatics internal teams to devise
an approach. Since completing these studies, one report8 has
been published that discusses the issues related to NGS assay
validation, and a second publication10 has offered recom-
mendations that are aligned with our approach. In addition, the
College of American Pathologists checklists, used by many
clinical laboratories to monitor practices in support of
accreditation, have been updated to include items speciﬁc
to NGS assays (http://www.cap.org/apps/docs/laboratory_
accreditation/checklists/2012_checklist_brochure.pdf, last
accessed July 27, 2013).
The clinical assay described in this article has been in use for
more than 1.5 years. To date, we have screened more than
11,000 patients (from in vitro fertilization clinics across the
United States) for carrier status, and foundalmost 500 carriers in
14 disease-causing genes. We also have identiﬁed seven novel
variants, including one in CFTR. We outline our clinical expe-
rience with this assay later, and discuss the lessons learned and
describe themutations detected thus far in this cohort of patients.
Materials and Methods
Samples
Genomic DNA was purchased from the Coriell Cell Re-
positories (Camden, NJ) or isolated from whole blood by the
Gentra Puregene method (Qiagen, Valencia, CA). DNA was
quantitated using a NanoQuant Plate (Tecan, San Jose, CA).
Controls
Nuclease-free water (Sigma, St. Louis, MO) and two DNA
controls, NA11284, which contains mutations in the CFTR
gene (p.F508del/p.R560T), and NA00502, which contains
mutations in the HEXA gene (c.1278insTATC/c.1421þ1
G>C), were purchased fromCoriell Cell Repositories and were
included in all runs.
Next-Generation DNA Sequencing
Next-generation DNA sequencing has been described previ-
ously.1 Brieﬂy, multiplex target capture using tiled, molecular
inversion probes is followed by incorporation of molecular
barcodes and Illumina (San Diego, CA) sequencing adapters.
The product then is sequenced using the Illumina Hiseq2000
system. Data analysis proceeds using a combination of open-
source and internally developed tools for sample demultiplex-
ing, read alignment, genotype calling, and functional annotation.
Subsequently, additional qualitymetrics are applied at the assay,
sample, and variant levels, and nonreference calls are ﬁltered
using an in-houseedeveloped database of variants.182Reagents and Equipment
Details of reagents and equipment used for the validation
studies are provided in Supplemental Tables S1 and S2.
Quality Scores for Data Analysis
Three different types of quality scores were used to assess
data in this validation: sample quality scores are indicative
of the overall quality of a given sample’s data, whereas the
run quality scores are indicative of the overall quality of a
run’s data. Variant quality scores were used to assess
sample-speciﬁc variant calls. Data that did not pass run or
sample quality score criteria were marked as a “failed
analysis” and were not evaluated further.
Sample Quality Scores
Sample quality score 1 (SQS1) is a fraction of callable bases: a
genomic position is deﬁned as “callable” if the call for this
position passesmultiple quality ﬁlters including having a depth
greater than 50. The fraction of callable bases is the number of
bases considered callable in the sample divided by the number
of bases targeted by the assay. It is also the number of bases
that pass both QS1 and QS2 thresholds (see variant quality
scores, later). The threshold is 0.9 (90% of captured bases are
callable). In clinical practice, any sample with less than 99% of
bases callable is repeated to obtain a more complete sequence.
SQS2 is the number of uncallable variant database entries,
that is, the number of Good Start Genetics, Inc. (GSG) variant
database entries that were not callable for a given sample.
The threshold is 10 (of 981) uncallable database positions. In
clinical practice any uncalled position is sequenced by Sanger
methodology.
Run Quality Scores
The run quality score 1 (RQS1) is the number of samples
failing SQS1 or SQS2. The threshold is 20; RQS2 is the
number of discordant genotype calls for control 1 (NA11284),
the threshold is 0; RQS3 is the number of discordant genotype
calls for control 2 (NA00502), the threshold is 0; RQS4, 5, and
6 are related to the detection of sample contamination from
unexpected molecular barcodes, library barcode sequence
cross-over rate, and mapped negative control reads, respec-
tively; and RQS7 is the number of samples with zero associ-
ated reads, the threshold is 1.
Variant Quality Scores to Determine Callability
To identify low-conﬁdence calls, we used thresholds on two
quality scores (statistics) associated with each genotype call.
These were depth of coverage (QS1) and strand bias (QS2).
Thresholds for each of these parameters have been set
empirically using data from previous analytic studies.1 Any
genotype call with a genomic position in the variant databasejmd.amjpathol.org - The Journal of Molecular Diagnostics
Carrier Screening Using NGSthat does not meet these criteria is ﬂagged as uncallable for
the sample under consideration.
Cross-Validation and Performance Statistics
When runs included set 1 samples (fully characterized in a
previous study1), data were subject to cross-validation
analysis. All sequence changes that differed from refer-
ence, irrespective of the clinical relevance, were assessed.
Runs were compared sample-by-sample. Each variant was
given one of the following mutually exclusive labels: true
positive if the variant was reported at the same genomic
position with the same lesion (alternative sequence) in the
same sample; false positive (FP) if the variant was detected
at a given position and sample in the validation for clinical
use data, but not in the previous study; and false negative
(FN) if the variant was detected at a given position and
sample in the previous study, but not in the validation for
clinical use data. Each FP variant was subject to a manual
review of next-generation sequence data (reads) and Sanger
reference data (if available). Systematic sequencing artifacts
that resulted in frequent FP variant calls were recorded and
performance statistics were calculated for each run.
Sanger Sequencing
PCRprimerswere developed for each regionof interest.Brieﬂy,
30-mL reactionswere conductedwith 100 ng of genomic DNA,
1 U of AmpliTaq Gold (Applied Biosystems, Grand Island,
NY), and 1 mmol of each PCR primer in a PCRmix containing
5% dimethyl sulfoxide (vol/vol), 1 mol/L betaine, 2.5 mmol/L
magnesium chloride, 1 mmol/L dNTPs (total), and 1
GeneAmp PCR Gold Buffer (Applied Biosystems, Brea, CA).
Cycling conditions were as follows: 95C for 10 minutes, 30
(95C for 30 seconds, 60C for 30 seconds, 72C for 30 sec-
onds), 72C for 10minutes, and 8C forever. PCRprimers used
were as described by Jones et al,11 except M13 tails were
removed. PCR products were puriﬁed using AMPure BeadsTable 1 Summary of Validation Studies
Run ID Purpose Notes
CV1-1 Accuracy
CV1-2 Accuracy
CV2-1 Lot-to-lot (lot 1 vs lot 2) Reagent lot 2 (differ
sub-lot of lot 1 MI
CV2-2 Lot-to-lot Reagent lot 1; MIP lo
CV4 Limit of detection CV4 and CV6-2 are on
CV5 Temperature assessment CV5-2 and CV7 are on
CV6-1 Reproducibility Intra-assay: day 1
CV6-2 Reproducibility Interassay: day 2
CV6-3 Reproducibility Different operator an
CV7 Blinded accuracy
Unless otherwise stated, reagent lot 1, operator 1, and instrument 1 were used.
*Molecular inversion probes (MIPs) are phosphorylated as a batch before use, w
(compared with CV1-1). CV2-2 used a completely new lot of MIPs.
The Journal of Molecular Diagnostics - jmd.amjpathol.org(Beckman Coulter, Brea, CA), and chain termination bidirec-
tional Sanger sequencing was performed on an ABI 3730xl
according to standard protocols. Data were analyzed using
mutation surveyor (SoftGenetics, State College, PA).
Results
Validation of a Carrier Screening Assay for Clinical Use
Two sets of samples were used for the clinical validation.
Set 1 consisted of samples thoroughly characterized by
Sanger sequencing during previous studies.1 They consisted
of a mix of HapMap/Human Variation Panel samples (to
ensure representation of different ethnic groups) and sam-
ples containing known mutations for the genes of interest. A
list of the set 1 samples is provided in Supplemental Table
S3. A second set of samples, set 2, consisted of Coriell DNA
with known mutation status, 10 DNA samples from external
laboratories (known mutation status; various extraction
methodologies), and 49 blood samples extracted at GSG.
There was some overlap in the Coriell samples used be-
tween sets 1 and 2. A list of the set 2 samples is provided in
Supplemental Table S4. Overall, 221 unique samples were
contained within sets 1 and 2.
The validation for clinical use (“clinical validation,” sub-
sequently referred to as “CV”) for the NGS assay was per-
formed as summarized in Table 1. Each study is described in
more detail later. All studies passed the RQS criteria.
The general acceptance criteria for these studies were as
follows: i) all previously deﬁned, clinically relevant muta-
tions must be detected as expected (false-negative rate of zero
at clinically relevant positions) for all samples that met the
SQS1 and 2 criteria; ii) the number of failing runs must be one
or less for the planned studies; iii) the overall sample fail rate
(samples failing SQS1 or SQS2) must be <3% (with the
exception of the limit of detection and temperature assess-
ment studies). Additional criteria were applied when speci-
ﬁed for each study described later. Note that false-positiveSamples
Set 1
Set 2
ent critical reagents;
Ps)*
Subset of set 1
t 2 Subset of set 1
the same run Subset of set 1 samples at different
concentrations
the same run Blood samples (not set 1 or 2)
Subset of set 1 in duplicate
Subset of set 1
d instrument: day 3 Subset of set 1 in duplicate
Subset of sets 1 and 2
CV1-1 was used as the lot 1 run for comparison in reagent lot-to-lot studies.
hich generates a sub-lot. CV2-1 used the lot 1 MIPs but a different sub-lot
183
Hallam et alresults were not considered from an acceptance criteria
perspective because Sanger sequencing would be used in
clinical practice to determine the true status. Therefore, the
main concern was whether the amount of Sanger sequencing
generated could be managed in the laboratory given resource
constraints. This is discussed further later.
A summary of the expected versus observed results for
all set 1 and 2 samples across all studies is provided in
Supplemental Table S5. False-positive results are not shown
in Supplemental Table S5 because these were assessed by
Sanger sequencing and hence would be corrected before
clinical result reporting. All runs passed the RQS criteria and
hence this acceptance criterion was met.
Accuracy (CV1-1 and CV1-2)
All set 1 and set 2 samples were run through the assay, in
experiments CV1-1 and CV1-2, respectively. Assessing the
accuracy data for all samples of known genotypes from a
clinical perspective, all expected mutations were detected
(ie, there were zero FNs). Therefore, our accuracy accep-
tance criteria were met.
In addition, all next-generation sequenced base positions
(irrespective of clinical relevance) were assessed for each
sample in the CV1-1 data set and were compared with their
respective counterparts in the known sequence to assess the
concordance and detection rates. This was possible because
all samples were previously fully characterized, as noted
earlier. In other words, all base positions in the sequence for
each sample were compared for genotype concordance.
There were no FN and nine FP variant calls. Hence, the
genotype concordance met the acceptance criterion of
99.999%, as shown:

1 9 FP
6;403;266 callable bases

 100%Z99:9998% ð1Þ
DNA Source
The primary purpose of the blood samples included in set 2
was to assess the overall quality and callability in samples
extracted by our methodology versus the Coriell cell lineFigure 1 Variant quality metric distributions. A: Depth of coverage, quality
samples in blue). B: Depth of coverage distributions for each CV run. C: Qualit
each CV run.
184DNA. The comparison of DNA source (blood or Coriell)
using distribution of variant level parameters showed that
there was no signiﬁcant variation in quality distributions for
depth of coverage (QS1, P Z 0.20), strand bias (QS2,
PZ 0.59), or quality over depth (QS3, PZ 0.48) (Figure 1).
P values were calculated using the Wilcoxon rank-sum test
with continuity correction.
Note that three reportable mutations were detected by
NGS in the unknown blood samples (set 2); all three were
conﬁrmed with Sanger sequencing.
Precision/Reproducibility (CV6-1, CV6-2, and CV6-3)
A subset of samples from set 1 were run in duplicate in a
single assay (intrarun reproducibility). This same subset then
was run on a separate day by the same operator using the
same reagents and instruments (interrun reproducibility). The
intrarun reproducibility study was replicated using a different
instrument and operator (instrument and operator reproduc-
ibility). Note that although multiple samples can be processed
simultaneously in an NGS run, validation studies require
multiple runs to assess different conditions. Because the cost
and time required for each run is high, it is necessary to ﬁnd
the most efﬁcient manner possible to assess all required
variables. Therefore, multiple parameters often were assessed
in a run when possible and reasonable because of these cost
constraints. This approach also is used for performing reagent
prequaliﬁcation; parameters subsequently are separated only
when the assay parameters do not pass acceptance criteria.
The use of set 1 samples for this study permitted cross-
validation to previous data and showed zero FN results,
therefore showing good precision of the assay. More infor-
mation is provided in Table 2, which provides a summary of
the FP and FN results for each CV run containing set 1
samples. The raw true positive, FP, and FN values represent
all sequence changes observed across all regions detected,
irrespective of whether the sequence change was clinically
signiﬁcant. The reported FP and FN values are based only on
positions that are considered clinically important. Note that for
each run, some samples were not assessed because they failed
the callability criteria (SQS1). One FN variant was observed,
a deletion mutation BCKDHA c.861_868delAGGCCCCG, in-by-depth, and strand bias for each DNA source (blood in red and Coriell
y-by-depth distributions for each CV run. D: Strand bias distributions for
jmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 2 Cross-Validation Performance Statistics
Run identiﬁer (purpose):
All known
mutations
detected? Raw TP Raw FP Raw FN Report FP Report FN
CV-1-1 accuracy Yes 3918 (25) 15 (9) 4 (22) 0 (1) 0 (0)
CV2-1 reagent lot-to-lot Yes 3889 (21) 5 (10) 3 (10) 0 (0) 0 (0)
CV2-2 reagent lot-to-lot No 3788 (20) 3 (9) 3 (12) 1 (2) 0 (1)
CV4 and 6-2 limit of detection and interrun
reproducibility
Yes 3864 (15) 36 (9) 3 (3) 10 (3) 0 (0)
CV6-1 intrarun reproducibility No 3926 (21) 3 (5) 2 (12) 0 (1) 0 (1)
CV6-3 reproducibility: operator and instrument Yes 3820 4 2 0 0
For each cell, the value for assessment of substitutions is given ﬁrst followed by the value for insertions and deletions in parentheses sample GM00649
BCKDHA c.861_868delAGGCCCCG.
TP, true positive.
Carrier Screening Using NGSCV runs CV2-2 and CV6-1. It was unclear if this was owing
to the quality of the DNA sample or the variant itself. Because
this variant is expected to exist at extraordinarily low fre-
quency it was removed from the panel (a rare example of a
mutation that was considered not frequent enough to warrant
an alternate methodology for detection). Note that this variant,
because it generates a frame-shift, could be detected and re-
ported to the clinical laboratory directors via the novel
reportable detection pathway.
An assessment of all runs for overall quality parameters is
provided later and shows assay reproducibility. Quality
score distributions were consistent across all runs (Figure 1).
Variability as a result of differences in sample sizes and run
conditions was within the expected range. True positive
heterozygous substitutions provided a median allele ratio of
0.5 for all runs and variability was very low. As expected,
the median allele ratio for insertions and deletions was lower
(0.34), indicating a slight reference bias compared with
substitutions. Variability was also higher for insertions and
deletions (Figure 2).
The three sets of distributions shown here indicate
there is no real difference at the variant level for any of
these three indicators of capture reaction and sequencing
performance.Figure 2 Reference bias. Cumulative allele ratio densities are shown for
all TP heterozygous substitutions and insertions and deletions. The median
density and expected allele ratio are shown, respectively, as horizontal and
vertical gray dashed lines.
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CV2-2)
A subset of samples from set 1 were analyzed with a different
vendor lot of each critical reagent or reagent mix (lot 2). The
comparator lot (lot 1) was the reagent set used for the accu-
racy experiment (CV1-1) described earlier. Reagents desig-
nated as critical included all enzymes, dNTPs, primers and
Illumina cluster kits, ﬂow cells, and sequencing by synthesis
kits. The molecular inversion probes used for the assay are
phosphorylated as a batch before use; this generated a sub-
lot. Two lot-to-lot runs therefore were completed; CV2-1
used molecular inversion probe lot 1 but a different sub-lot
(phosphorylation), all other critical reagents were from lot 2.
CV2-2 used reagent lot 1 but a new lot of molecular inversion
probes (lot 2). Cross-validation to assess genotype concor-
dance showed zero FN variants (those that are clinically
relevant and those that are not) on both reagent lot runs.
Allowable Variability of Input DNA (CV4)
The purpose of this study was to determine the performance
of a10% deviation from the optimal DNA input amount of
1.5 mg (the optimal DNA input amount was determined
during the development process). All DNA for clinical
testing is quantiﬁed before use in the NGS assay and an input
of 1.5 mg DNA input quantity is targeted. We would expect
the quantiﬁcation error to be less than 10% in practice. A
subset of samples from set 1 was assayed in at each of the
following input amounts: 1.35 mg, 1.5 mg, and 1.65 mg. The
results show that input DNA concentration has the expected
marginal effect on callability (SQS1) (Figure 3). There were
no FN variants for this run. All FP variants were systematic
and were represented equally among the different DNA input
amounts, indicating that sequencing errors were not affected
by input DNA concentration.
Interfering Substances
Potential sources of interfering substances include bilirubin,
hemoglobin, Na2 EDTA, and triglycerides. However, previous185
Figure 3 Effects of varying amounts of DNA on sample callability. CV-4.
Red 135 indicates 1.35 mg DNA input, green 150 indicates 1.5 mg DNA
input, and blue 165 indicates 1.65 mg DNA input.
Figure 4 Percent callable bases for temperature assessment data. CV5
(shown in red, orange, and yellow). The percent callability of samples with
the blinded accuracy data, CV-7 (shown in green), which uses Coriell
samples, is also shown as a comparator.
Hallam et alstudies by other investigators have shown that DNA testing is
not subject to interference from these substances (http://www.
accessdata.fda.gov/cdrh_docs/reviews/K043011.pdf, last
accessedMay 1, 2013). In addition, because 49 blood samples
were included in the accuracy assessment studies and 60 blood
samples were included in the temperature assessment study,
most or all of these substances were assessed. Note also that
the extraction procedure yields high-purity DNA and that an
assessment of the 260 of 280 ratio was obtained for each
sample.
Temperature Assessment (CV5)
In general, samples for DNA testing are shipped overnight at
ambient temperature and are not considered to be particularly
sensitive to temperature. However, because NGS is a new
technology in the clinical carrier screening ﬁeld, we wanted
to determine whether temperature extremes during the
shipping process would impact the sample integrity. The
temperature conditions were chosen based on data obtained
from TempTales devices (Sensitech, Inc., Beverly, MA) that
were shipped from two different locations during the sum-
mer months (Texas and California) using our shipping
containers. These devices record temperature data every few
minutes and the data obtained subsequently can be down-
loaded onto a PC. The data showed maximum temperatures
of 110C for 2 to 3 minutes. The extreme temperature con-
ditions were selected to mimic worse-case scenarios.
Sixty blood samples were exposed to three different
temperature conditions. Set A (20 samples) was subjected to
three freeze/thaw cycles over a 24-hour period before
extraction. Set B (20 samples) was stored refrigerated. Set C
(20 samples) was exposed to 110C for 8 hours, transferred186to 80C for 16 hours, and then stored refrigerated until
extraction. The acceptance criteria were as noted earlier plus
the assay and sample quality scores needed to be within
established thresholds regardless of temperature exposure.
The results (Figure 4) show that the temperature treat-
ments described do not reduce the percentage of callable
bases. Interestingly, DNA extracted using external source
material and protocols (Coriell) had signiﬁcantly lower
callability (SQS1 value) compared with DNA extracted
from blood using our current protocol. Note that the fraction
of bases callable (SQS1) is not the same as the average
depth of coverage because the former is the fraction of bases
sequenced above a given depth and therefore relates to the
uniformity with which all targets within a sample are
captured and sequenced, whereas the latter simply describes
the average number of times each target base is sequenced.
Hence, the depth between experiments can appear statisti-
cally indistinguishable, whereas SQS1 may appear different.
Blinded Accuracy/Internal Proﬁciency Assessment
(CV7)
Eighty samples were chosen at random from sample sets 1
and 2, and their identity was hidden from the run operator
and reviewer until all tests and results were complete. All
expected mutations were detected and hence the acceptance
criteria were met.
Expected Repeat Rate
An important component of our assessment of the readiness
of the assay for clinical use, and an acceptance criterion, was
the repeat rate per run. The amount of time needed to re-run a
sample, and the cost of this technology can be problematic,jmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 3 The Percentage of Failed Samples for All Variants in All
Genes Analyzed
CV study number
Failed samples
per run, %
CV1-1 accuracy 0.07
CV1-2 accuracy 2.67
CV2-1 lot-to-lot 0.13
CV2-2 lot-to-lot 2.67
CV4/6-2 limit of detection/reproducibility 6.67
CV5/7 temperature/blinded accuracy 1.33
CV6-1 reproducibility 0.00
CV6-3 reproducibility 1.33
Average 1.86
Table 4 Carrier Rates Observed by Disorder in the Study
Population (Multi-Ethnic)
Disorder and gene Carrier frequency
Bloom syndrome, BLM 1 in 946 (3/2838)
Canavan disease, ASPA 1 in 189 (16/3017)
Cystic ﬁbrosis, CFTR 1 in 30 (333/10085)*
Dihydrolipoamide dehydrogenase
deﬁciency, DLD
1 in 525 (4/2101)
Familial dysautonomia, IKBKAP 1 in 301 (10/3009)
Familial hyperinsulinism, ABCC8 1 in 263 (8/2105)
Fanconi anemia group C, FANCC 1 in 482 (6/2890)
Glycogen storage disease,
type 1A, G6PC
1 in 263 (8/2102)
Maple syrup urine disease, type A,
BCKDHA
1 in 2110 (1/2110)
Maple syrup urine disease, type B,
BCKDHB
1 in 352 (6/2110)
Mucolipidosis, type IV, MCOLN1 1 in 722 (4/2890)
Niemann-Pick disease, type AB, SMPD1 1 in 578 (5/2889)
Tay-Sachs disease, HEXA 1 in 93 (36/3336)
Usher syndrome, type 1F, PCDH15 1 in 700 (3/2101)
Usher syndrome, type III, CLRN1 1 in 526 (4/2103)
*Not including the compound heterozygote.
Carrier Screening Using NGShence a very low repeat rate was desired. Adhering to strict
DNA quantiﬁcation criteria (as noted earlier) helps to reduce
the repeat rate. An assessment of the repeat rate was based on
the number of samples that failed either SQS1 or SQS2 and is
shown in Table 3. Overall, this met the acceptance criteria of
less than 3% because the average percentage repeat rate was
1.86%. In addition, note that this average includes the limit of
detection and temperature assessment studies. This rate is
expected to be an upper bound for clinical operations because
we already showed during the validation studies that DNA
extracted from blood at our facility provided a superior per-
formance compared with Coriell DNA. Our experience in
clinical practice to date is a fail rate of less than 1%. (Note
that sufﬁcient sample typically is available to complete all
testing, including any required repeats and conﬁrmations.)
As stated previously, all positive results onNGS are assessed
by Sanger sequencing. This therefore includes both FP and
true-positive results. Obviously, the true-positive rate is ﬁxed
by the carrier rate for each disorder, but the FP rate is driven by
assay quality. In the clinical validation studies described here,
approximately 5% to 10% of samples that passed the sample
quality thresholds were found to have one to two FPs.
Overall, all acceptance criteria were met for the validation
studies: there were no run failures, the repeat rate was within
preset limits, and there were no FN results after the removal
of a rare mutation in BCKDHA that was detected incon-
sistently in a Coriell DNA sample of questionable integrity.
Experience with the Assay in Clinical Practice
Here, we report on the results of 11,691 cases from patients
undergoing carrier testing in an in vitro fertilization setting.
The repeat rate has been below that observed in the vali-
dation, as expected, and similar for the FP rate (the number
of samples requiring Sanger assessment that do not have the
mutation indicated). With regard to FP results, we saw a
small number of systematic variants, all of which have been
sequenced multiple times across many samples, and now
readily are distinguished from true positives on the basis of
their characteristic genomic position and sequence change.
The list of all mutations found for each gene assessed by
NGS is provided in Supplemental Table S6. A total of 87The Journal of Molecular Diagnostics - jmd.amjpathol.orgdistinct mutations in 14 different genes were found. Fre-
quency is the number of instances of the mutation observed
in our data. The two most frequent mutations were CFTR
F508del (199 þ 1 compound heterozygote), and CFTR
p.R117H in conjunction with c.1210-12T[7] (30 patients).
The third most frequent mutation that was found in 26 pa-
tients was HEXAc.1274_1277dupTATC. All other muta-
tions occurred in fewer than 10 patients (carrier frequencies
discussed later).
The Test Status column in Supplemental Table S6 indicates
whether the mutation was found only by the GSG screening
panel, generally tested in expanded mutation panels,
commonly tested in most panels, or a novel (ie, previously
unreported pathogenic) variant we detected. Of note is the fact
that commonly used mutation panels would have missed
many of these mutations. This includes those indicated by
either “GSG Only” or “Novel” in the Test Status column.
Seven novel mutations were found in seven patients. The
novel mutations found included one in CFTR, c.1526delG,
which was found in an Asian patient. This is remarkable
because CFTR is an extremely well-studied gene with
approximately 2000 mutations already known per the
Hospital for Sick Children CFTR Mutation Database web-
site (http://www.genet.sickkids.on.ca/StatisticsPage.html,
last accessed May 26, 2013). The overall carrier frequency
observed for cystic ﬁbrosis in this data set is 1 in 30, as
shown in Table 4. This is likely the result of screening a
broad range of ethnicities (Supplemental Table S6).
Other novel truncating mutations were found in G6PC,
CLRN1, MCOLN1, ABCC8, BCKDHB, and IKBKAP. In
addition, 16 unique mutations that were tested for only in
our panel also were identiﬁed, representing 17 carriers. In
total, 23 unique mutations and 24 carriers would not have187
Hallam et albeen detected using any other carrier screening panel that is
clinically available. Because of the high detection rates
using our NGS technology, the calculated reproductive risk
after testing both partners is typically very low. However,
when one partner is found to be a carrier, our licensed ge-
netics professionals are available to counsel patients and
couples and provide information about options for subse-
quent testing, including testing with a standard panel, testing
with the panel we have described here, or testing with full
gene sequencing (with the inclusion of all detected muta-
tions and variants), depending on what is available for the
gene in question.
The carrier frequency for our patient cohort is shown in
Table 4. The highest carrier frequencies are cystic ﬁbrosis,
with a rate of 1 in 30, and Tay-Sachs disease, with a fre-
quency of 1 in 93. The lowest carrier frequencies found
were for MSUD, type A (1 in 2110), and Bloom syndrome
(1 in 946), as expected.Discussion
We have described a highly sensitive NGS-based assay
system for carrier screening that offers many advantages over
traditional genotyping methodologies, and shows high ac-
curacy, precision, reproducibility, and robustness for clinical
use. The assay performed with high veracity across all vari-
ables assessed and that are expected to be encountered in
typical clinical operations. Although FP results are generated
from the NGS assay, all are systematic novel (ie, previously
unreported) variants that can be recognized as such by their
quality parameters; in addition, follow-up evaluation by
Sanger sequencing allows reporting of only true-positive
results. The assay has comparable turnaround time (currently
10 to 14 days) with traditional genotyping methodologies.
The assay reagent costs also are comparable with genotyping
arrays, a technology that NGS could replace; however, at this
time, the capital costs may be different.
One of the main goals of developing the NGS assay for
clinical carrier screening was to provide assessment for
disorders recommended by professional societies at much
greater depth than possible with other methodologies.
Rather than merely testing for a limited set of mutations, we
assessed all known, clinically important, pathogenic muta-
tions, as well as novel mutations that would be predicted to
be pathogenic based on the type of sequence change (ie,
nonsense, frame-shift, invariant splice site). Although other
investigators have looked at sequencing multiple genes for
carrier testing purposes in a research setting,12 this has not
been performed previously on a large set of samples in
clinical practice. This study therefore provides a unique
opportunity to better assess carrier status and mutation
spectrum in a broader range of patients and ethnicities.
Our initial clinical experience using this approach to
screen 11,691 in vitro fertilization patients has diagnosed
447 carriers consisting of 87 unique mutations in 14 different188genes. The most frequently found variants were CFTR
p.F508del, CFTR p.R117H, and HEXA c.1274_1277dup-
TATC, which were found in 200, 37, and 26 patients,
respectively (200 CFTR p.F508del includes the compound
heterozygote). The remaining mutations occurred in fewer
than 10 patients each.
From a carrier screening perspective, 3.8% of individuals
tested were found to be carriers of one or more of the genes
assessed by NGS. Note that this is a conservative number
because additional tests with relatively high carrier fre-
quencies also commonly are assessed by non-NGS tech-
nologies during carrier screening (eg, fragile X syndrome
and spinal muscular atrophy) and not all NGS genes were
ordered by the referring health care provider. Hence, when
viewed from this perspective, carriers of signiﬁcant genetic
disorders are likely to occur in a mixed ethnic population at
a rate of 1 in 20 to 1 in 25.
The carrier frequencies in our patient cohort are generally in
agreement with the available literature and range from 1 in 30
for cystic ﬁbrosis to 1 in 2110 forMSUD, type A. The 1 in 30
carrier frequency for cystic ﬁbrosis is a little surprising given
that we are testing a diverse ethnic population. We intend to
assess this further once a larger cohort has been tested.
Importantly, approximately one quarter of the speciﬁc
mutations we have found would have been missed by the
more commonly used limited mutation panels, including 16
previously known mutations that were tested for only in our
panel, and 7 novel truncating mutations we have discovered
in the CFTR, G6PC, CLRN1,MCOLN1, ABCC8, BCKDHB,
and IKBKAP genes. Failure to detect these variants would
have resulted in 24 undiagnosed carriers because one of the
mutations was found in 2 different individuals. In addition,
we are seeing a spectrum of mutations across ethnic groups
that likely would be challenging to detect with non-NGS
technologies. These missed mutations could put carrier
couples at increased risk of having a child with a costly and
debilitating disease.
We are detecting common, rare, and novel mutations in a
clinical setting, a signiﬁcant number of which are not
included in other carrier screening panels. We therefore have
shown the power of NGS technology in a carrier screening
setting for increasing carrier detection rates for a number of
severe, prevalent, and guideline-recommended disorders,
something that is particularly valuable in a diverse ethnic
population such as now exists in the United States.
Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.jmoldx.2013.10.006.
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